Cargando…
Losartan ameliorates dystrophic epidermolysis bullosa and uncovers new disease mechanisms
Genetic loss of collagen VII causes recessive dystrophic epidermolysis bullosa (RDEB)—a severe skin fragility disorder associated with lifelong blistering and disabling progressive soft tissue fibrosis. Causative therapies for this complex disorder face major hurdles, and clinical implementation rem...
Autores principales: | Nyström, Alexander, Thriene, Kerstin, Mittapalli, Venugopal, Kern, Johannes S, Kiritsi, Dimitra, Dengjel, Jörn, Bruckner-Tuderman, Leena |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley & Sons, Ltd
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4568953/ https://www.ncbi.nlm.nih.gov/pubmed/26194911 http://dx.doi.org/10.15252/emmm.201505061 |
Ejemplares similares
-
Dystrophic Epidermolysis Bullosa: Secondary Disease Mechanisms and Disease Modifiers
por: Nyström, Alexander, et al.
Publicado: (2021) -
EGFR inhibition for metastasized cutaneous squamous cell carcinoma in dystrophic epidermolysis bullosa
por: Diociaiuti, Andrea, et al.
Publicado: (2019) -
Pro‐inflammatory immunity supports fibrosis advancement in epidermolysis bullosa: intervention with Ang‐(1‐7)
por: Bernasconi, Rocco, et al.
Publicado: (2021) -
Newer Treatment Modalities in Epidermolysis Bullosa
por: Bruckner-Tuderman, Leena
Publicado: (2019) -
Rat Model for Dominant Dystrophic Epidermolysis Bullosa: Glycine Substitution Reduces Collagen VII Stability and Shows Gene-Dosage Effect
por: Nyström, Alexander, et al.
Publicado: (2013)